OCEA vs. ASLN, PBLA, CWBR, SXTC, HEPA, EVFM, TRVN, ATHX, SYRS, and BPTSY
Should you be buying Ocean Biomedical stock or one of its competitors? The main competitors of Ocean Biomedical include ASLAN Pharmaceuticals (ASLN), Panbela Therapeutics (PBLA), CohBar (CWBR), China SXT Pharmaceuticals (SXTC), Hepion Pharmaceuticals (HEPA), Evofem Biosciences (EVFM), Trevena (TRVN), Athersys (ATHX), Syros Pharmaceuticals (SYRS), and Biophytis (BPTSY). These companies are all part of the "pharmaceutical preparations" industry.
Ocean Biomedical vs.
ASLAN Pharmaceuticals (NASDAQ:ASLN) and Ocean Biomedical (NASDAQ:OCEA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability, valuation and community ranking.
ASLAN Pharmaceuticals received 196 more outperform votes than Ocean Biomedical when rated by MarketBeat users. However, 100.00% of users gave Ocean Biomedical an outperform vote while only 63.49% of users gave ASLAN Pharmaceuticals an outperform vote.
ASLAN Pharmaceuticals has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Ocean Biomedical has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.
58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. Comparatively, 24.6% of Ocean Biomedical shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by company insiders. Comparatively, 73.5% of Ocean Biomedical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
ASLAN Pharmaceuticals has higher revenue and earnings than Ocean Biomedical. ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio than Ocean Biomedical, indicating that it is currently the more affordable of the two stocks.
Ocean Biomedical's return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity.
In the previous week, ASLAN Pharmaceuticals' average media sentiment score of 0.00 equaled Ocean Biomedical'saverage media sentiment score.
Summary
ASLAN Pharmaceuticals beats Ocean Biomedical on 6 of the 11 factors compared between the two stocks.
Get Ocean Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCEA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ocean Biomedical Competitors List
Related Companies and Tools
This page (NASDAQ:OCEA) was last updated on 5/24/2025 by MarketBeat.com Staff
Buy OCEA Stock Free OCEA Stock Alerts